Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substances: Ethinyl estradiol, Norelgestromin
Strength: 600 µg + 6 mg
Dosage form: parche transdérmico
Route: vía transdérmica
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 7 Jul 2016
Registration: 02223001IP1
Marketing authorisation holder: Janssen-Cilag International N.V
Procedure: EU centralised
Supply: Medicamento Sujeto A Prescripción Médica

Ethinyl estradiol + Norelgestromin · 600 µg + 6 mg · parche transdérmico

Spain

Evra 203 Microgramos/24 Horas + 33,9 Microgramos/24 Horas Parche TransdermicoEthinyl estradiol + Norelgestromin · 600 µg + 6 mg · parche transdérmicoSpain

Evra 203 Microgramos/24 Horas + 33,9 Microgramos/24 Horas Parche TransdermicoEthinyl estradiol + Norelgestromin · 6 mg + 600 µg · parche transdérmicoSpain

Evra 203 Microgramos/24 Horas + 33,9 Microgramos/24 Horas Parche TransdermicoEthinyl estradiol + Norelgestromin · 600 µg + 6 mg · parche transdérmicoSpain

Evra 203 Microgramos/24 Horas + 33,9 Microgramos/24 Horas Parche TransdermicoEthinyl estradiol + Norelgestromin · 6 mg + 600 µg · parche transdérmicoSpain